Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide + hydroxychloroquine combination therapy for primary Sjogren syndrome
2020-001933-11Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Leflunomide + hydroxychloroquine with Placebo + placebo (2 arms). Primary endpoint: Change in ESSDAI from baseline to week 24. Started Jun 2021; status: active.
02
Drugs
leflunomidehydroxychloroquine
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2020-001933-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001933-11.